Appian Provides New Digital Solution for Pharmacovigilance Reporting to Bayer
Solution Optimizes Processes for Increased Efficiency
RESTON, Va. and FRANKFURT, Germany, June 28, 2018 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN) today announced that Bayer's Pharmaceuticals division has selected the Appian application platform to digitize and optimize its processes for requesting internal reports on pharmacovigilance (PV) data.
Complex IT systems, deployed over decades, often work in isolation and support just a very little piece of a process landscape. They focus on the specialties of their data types but not on people, their collaboration and sequence of activities. People have to remember many rules and process steps when they combine data manually from different sources.
By focusing on people and their collaboration, solutions built on Appian help to accelerate business improvement while providing the flexibility to review, improve processes and rules continuously. Tracking Key Performance Indicators (KPIs) is an integral part of all process implementations, providing insights and visibility across the business.
Appian delivers the starting point and comprehensive insights into the operational processes for generating listings and aggregate statistics on side effects, their medical contents and processing efforts. Appian offers modern interfaces that are powerful yet easy to use.
Appian's solution automates recurring decisions based on rules and supports approvals from mobile devices when required. As a result, tasks can be completed more efficiently while spending more time on higher value activities.
"The pharmaceutical industry has realized that it needs to implement digital technologies to remain competitive and successful. Increasingly strict regulations, cost pressure, and rising patient expectations challenge organizations. They are only able to fulfill these demands if the processes used for implementing rules and regulations are being simplified and streamlined - thereby ensuring pharmaceutical companies' competitive edge," said Evi Cohen, VP of Global Pharmaceuticals and Life Sciences, Appian.
Appian provides a leading low-code software development platform that enables organizations to rapidly develop powerful and unique applications. The applications created on Appian's platform help companies drive digital transformation and competitive differentiation. For more information, visit www.appian.com.
For more press-related information, please contact:
Director of Media Relations
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Appian Corporation via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Compuware Acquires XaTester and Partners with Parasoft to Deliver Essential Automated Unit Testing to Mainframe DevOps Teams18.7.2018 12:00 | Pressmeddelande
Topaz Further Established as the Leading Solution for Continuously Improving Velocity, Quality and Efficiency of Enterprise Systems Large enterprises must rigorously safeguard the quality of their mission-critical mainframe systems as digital demands drive them to develop and deploy mainframe code more quickly and frequently. With the acquisition of XaTester, new enhancements, and partnership with Parasoft, Compuware Topaz for Total Test is the clear leader in the automated unit testing essential for Agile and DevOps on the mainframe. With Topaz, developers at all skill levels can quickly and efficiently produce the highest-quality code for the mainframe-enabling enterprises to achieve the digital agility essential for success in fast-moving markets. DETROIT, July 18, 2018 (GLOBE NEWSWIRE) -- Compuware today announced a product acquisition, enhancements to Topaz for Total Test, and a partnership that together dramatically improve the ability of large enterprises to embrace Agile and De
Cryptomining Replaces Ransomware as Most Popular Cybercrime Malware18.7.2018 09:00 | Pressmeddelande
Analysis of vulnerability and threat trends shows cryptomining malware dominates threat landscape in the first half of 2018 SAN JOSE, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- Skybox® Security, a global leader in cybersecurity management, announced today the release of its mid-year update to the Vulnerability and Threat Trends Report which analyzes vulnerabilities, exploits and threats in play. The report, compiled by the team of security analysts at the Skybox® Research Lab, aims to help organizations align their security strategy with the reality of the current threat landscape. The mid-year update explores trends observed from January to June of 2018. One of the most significant findings is the replacement of ransomware as the cybercriminal tool of choice with cryptomining malware. In the last six months of 2017, ransomware accounted for 32 percent of attacks, while malicious cryptominers accounted for seven percent. By the first half of 2018, the figures had switched almost exactly
GridGain® Continues In-Memory Computing Industry Leadership in 201818.7.2018 09:00 | Pressmeddelande
GridGain Continues Rapid Growth, Delivers Product Innovations, Hosts Vital Industry Conferences and Earns Top Industry Accolades FOSTER CITY, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite(TM), today announced continuing strong momentum for the first half of 2018. Key achievements during the first half of the year included more new customer wins in the first half of 2018 than in all of 2017, launching major new products including GridGain Professional Edition 2.4 and GridGain Cloud, winning several top industry accolades, and driving continued growth of the popular In-Memory Computing Summit® in Europe. Growth New customer acquisition surged during the first half of 2018 with the company acquiring 40 percent more new customers than were signed in all of 2017. New customers acquired in 2018 include leading companies in financial services, transportation, telecommunications, retail, healthcar
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30 | Pressmeddelande
LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma
Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15 | Pressmeddelande
BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio
Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05 | Pressmeddelande
WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum